• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CRL3、ARIH1和NEDD4家族泛素连接酶对PD-L1泛素化的生化分析。

Biochemical analysis of PD-L1 ubiquitination by CRL3, ARIH1, and NEDD4 family ubiquitin ligases.

作者信息

Xie Guojiao, Gao Lin, Lu Renee, Tian Linxia, Zheng Tiantian, Li Xinning, Dang Yongjun, Cole Philip A, Yu Xian, Jiang Hanjie, Chen Zan

机构信息

Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Phase I Clinical Trial Center, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02215, USA.

出版信息

Structure. 2025 Aug 7;33(8):1304-1313.e4. doi: 10.1016/j.str.2025.05.005. Epub 2025 Jun 4.

DOI:10.1016/j.str.2025.05.005
PMID:40472843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12335357/
Abstract

As a key immune checkpoint ligand, PD-L1 is a critical target in cancer immunotherapy. While multiple E3 ubiquitin ligases including CRL3, ARIH1, and NEDD4 have been implicated in PD-L1 degradation, the precise enzymatic mechanisms remain unclear. In this study, we systematically compared the enzymatic activities of CRL3, ARIH1, and NEDD4 ligases toward the cytoplasmic domain of PD-L1 through in vitro reconstitution with purified components. ARIH1, rather than CRL3, independently ubiquitinates PD-L1. We reveal a mechanism where ARIH1 acts as a substrate receptor and cooperates with CRLs to catalyze PD-L1 ubiquitination. We also biochemically validated the E3 ligase activity of the NEDD4 family E3s toward PD-L1. By using liposomes in the enzymatic assays, we show that phosphorylation enhances PD-L1 ubiquitination through disrupting its membrane association. Our study provides further biochemical insights into PD-L1 ubiquitination, which advances our understanding of the molecular details of PD-L1 regulation.

摘要

作为一种关键的免疫检查点配体,程序性死亡配体1(PD-L1)是癌症免疫治疗中的一个关键靶点。虽然包括Cullin-RING连接酶3(CRL3)、含锚蛋白重复序列的E3泛素连接酶1(ARIH1)和神经前体细胞表达发育下调蛋白4(NEDD4)在内的多种E3泛素连接酶都与PD-L1的降解有关,但具体的酶促机制仍不清楚。在本研究中,我们通过用纯化的组分进行体外重组,系统地比较了CRL3、ARIH1和NEDD4连接酶对PD-L1胞质结构域的酶活性。ARIH1而非CRL3能独立地使PD-L1泛素化。我们揭示了一种机制,即ARIH1作为底物受体并与Cullin-RING连接酶(CRLs)协同催化PD-L1的泛素化。我们还通过生物化学方法验证了NEDD4家族E3对PD-L1的E3连接酶活性。通过在酶促测定中使用脂质体,我们表明磷酸化通过破坏PD-L1与膜的结合来增强其泛素化。我们的研究为PD-L1的泛素化提供了进一步的生物化学见解,这加深了我们对PD-L1调控分子细节的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/9d37b0a87ec7/nihms-2089986-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/e09de144cdc1/nihms-2089986-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/7774371375b8/nihms-2089986-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/2e3aad15db72/nihms-2089986-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/9d37b0a87ec7/nihms-2089986-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/e09de144cdc1/nihms-2089986-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/7774371375b8/nihms-2089986-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/2e3aad15db72/nihms-2089986-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35ec/12335357/9d37b0a87ec7/nihms-2089986-f0005.jpg

相似文献

1
Biochemical analysis of PD-L1 ubiquitination by CRL3, ARIH1, and NEDD4 family ubiquitin ligases.CRL3、ARIH1和NEDD4家族泛素连接酶对PD-L1泛素化的生化分析。
Structure. 2025 Aug 7;33(8):1304-1313.e4. doi: 10.1016/j.str.2025.05.005. Epub 2025 Jun 4.
2
Comprehensive database of human E3 ubiquitin ligases: application to aquaporin-2 regulation.人类 E3 泛素连接酶综合数据库:在水通道蛋白-2 调节中的应用。
Physiol Genomics. 2016 Jul 1;48(7):502-12. doi: 10.1152/physiolgenomics.00031.2016. Epub 2016 May 13.
3
The role of E3 ligases and deubiquitinases in PD-L1 regulation and the tumor microenvironment in renal cell carcinoma.E3 泛素连接酶和去泛素化酶在肾细胞癌中 PD-L1 调控及肿瘤微环境中的作用
Med Oncol. 2025 Jul 29;42(9):389. doi: 10.1007/s12032-025-02878-z.
4
Commissureless acts as a substrate adapter in a conserved Nedd4 E3 ubiquitin ligase pathway to promote axon growth across the midline.无连合蛋白在保守的Nedd4 E3泛素连接酶途径中作为底物衔接蛋白,以促进轴突越过中线生长。
Elife. 2025 May 23;13:RP92757. doi: 10.7554/eLife.92757.
5
The E3 Ubiquitin Ligase ARIH1 Facilitates Colorectal Cancer Progression by Promoting Oxidative Phosphorylation via the Mitochondrial Translocation of K63-Linked Ubiquitinated PHB1.E3泛素连接酶ARIH1通过促进K63连接的泛素化PHB1的线粒体易位来推动氧化磷酸化,从而促进结直肠癌进展。
Adv Sci (Weinh). 2025 Apr 26:e2501017. doi: 10.1002/advs.202501017.
6
Arkadia and Ark2C Promote Substrate Ubiquitylation with Multiple E2 Enzymes.Arkadia和Ark2C可与多种E2酶共同促进底物泛素化。
J Mol Biol. 2025 Sep 1;437(17):169259. doi: 10.1016/j.jmb.2025.169259. Epub 2025 May 30.
7
Optimum level of NEDD4 and its interaction with nsP3 are crucial to facilitate efficient Chikungunya virus (CHIKV) infection.NEDD4的最佳水平及其与nsP3的相互作用对于促进基孔肯雅病毒(CHIKV)的有效感染至关重要。
J Gen Virol. 2025 Aug;106(8). doi: 10.1099/jgv.0.002136.
8
HSV-1 UL56 protein recruits cellular NEDD4-family ubiquitin ligases to suppress CD1d expression and NKT cell function.单纯疱疹病毒1型UL56蛋白招募细胞内NEDD4家族泛素连接酶以抑制CD1d表达和NKT细胞功能。
J Virol. 2025 Apr 15;99(4):e0214024. doi: 10.1128/jvi.02140-24. Epub 2025 Mar 6.
9
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.肿瘤突变负荷与肿瘤微环境之间的相互作用可预测泛癌抗PD-1/PD-L1治疗的预后。
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
10
Cullin 3-mediated ubiquitination restricts enterovirus D68 replication and is counteracted by viral protease 3C.Cullin 3介导的泛素化作用限制肠道病毒D68的复制,并被病毒蛋白酶3C所抵消。
J Virol. 2025 Jun 17;99(6):e0035425. doi: 10.1128/jvi.00354-25. Epub 2025 May 21.

本文引用的文献

1
Protein semisynthesis reveals plasticity in HECT E3 ubiquitin ligase mechanisms.蛋白质半合成揭示了 HECT E3 泛素连接酶机制的灵活性。
Nat Chem. 2024 Nov;16(11):1894-1905. doi: 10.1038/s41557-024-01576-z. Epub 2024 Jul 19.
2
5,7,4'-Trimethoxyflavone triggers cancer cell PD-L1 ubiquitin-proteasome degradation and facilitates antitumor immunity by targeting HRD1.5,7,4'-三甲氧基黄酮通过靶向HRD1触发癌细胞PD-L1泛素-蛋白酶体降解并促进抗肿瘤免疫。
MedComm (2020). 2024 Jun 27;5(7):e611. doi: 10.1002/mco2.611. eCollection 2024 Jul.
3
Regulatory mechanisms of PD-1/PD-L1 in cancers.
PD-1/PD-L1 在癌症中的调控机制。
Mol Cancer. 2024 May 18;23(1):108. doi: 10.1186/s12943-024-02023-w.
4
Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.程序性死亡配体1与泛素化和去泛素化的调控串扰:对癌症免疫治疗的影响
Int J Mol Sci. 2024 Mar 3;25(5):2939. doi: 10.3390/ijms25052939.
5
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC.KEAP1 通过抑制 NSCLC 中的 PD-L1 表达促进抗肿瘤免疫。
Cell Death Dis. 2024 Feb 27;15(2):175. doi: 10.1038/s41419-024-06563-3.
6
BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.BCLAF1 结合 SPOP 以稳定 PD-L1 并促进肝癌的发展和免疫逃逸。
Cell Mol Life Sci. 2024 Feb 10;81(1):82. doi: 10.1007/s00018-024-05144-z.
7
Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy.针对 PD-L1 胞质结构域及其调控通路以增强癌症免疫治疗。
J Mol Cell Biol. 2024 Apr 10;15(11). doi: 10.1093/jmcb/mjad070.
8
Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy.针对 USP2 调节 VPRBP 介导的 p53 和 PD-L1 降解以用于癌症治疗。
Nat Commun. 2023 Apr 6;14(1):1941. doi: 10.1038/s41467-023-37617-3.
9
PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination.PD-L1 易位到质膜可通过 MIB2 泛素化实现肿瘤免疫逃逸。
J Clin Invest. 2023 Feb 1;133(3):e160456. doi: 10.1172/JCI160456.
10
Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation.通过靶向 TMUB1 调节 PD-L1 的多泛素化和糖基化来促进抗肿瘤免疫。
Nat Commun. 2022 Nov 14;13(1):6951. doi: 10.1038/s41467-022-34346-x.